COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Montero, Alberto J. [1 ]
Lopes, Gilberto [2 ]
机构：
[1] Univ Miami, Sylvester Canc Ctr, Coral Gables, FL 33124 USA
[2] Johns Hopkins Singapore Int Med Centr, Dept Med Oncol, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
Crizotinib; cost effectiveness analysis; economic asessment;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-048
引用
收藏
页码：S1211 / S1212
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT CONTAINING CRIZOTINIB FOR NON SMALL CELL LUNG CANCER (ALK plus ) PATIENTS
    Sabater Cabrera, E.
    Puente, J.
    Oyaguez, I
    Garcia-Campelo, R.
    Reguart, N.
    Rodriguez, D.
    Cobo, M.
    Soto, J.
    Moran, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A443 - A444
  • [2] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
    Ansgar Lange
    Anne Prenzler
    Martin Frank
    Heiko Golpon
    Tobias Welte
    J-Matthias von der Schulenburg
    [J]. BMC Pulmonary Medicine, 14
  • [4] A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
    Lange, Ansgar
    Prenzler, Anne
    Frank, Martin
    Golpon, Heiko
    Welte, Tobias
    von der Schulenburg, J-Matthias
    [J]. BMC PULMONARY MEDICINE, 2014, 14
  • [5] COST-EFFECTIVENESS OF CRIZOTINIB, CERITINIB, AND ALECTINIB AS FIRST-LINE TREATMENTS FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK plus ) METASTATIC NON-SMALL CELL LUNG CANCER
    Xuan, S.
    Ma, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S32 - S33
  • [6] Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer in Canada
    Hurry, Manjusha
    Zhou, Zheng-Yi
    Zhang, Jie
    Zhang, Chenxue
    Fan, Liangyi
    Rebeira, Mayvis
    Xie, Jipan
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (10) : 936 - 944
  • [7] Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
    Zeng, Xiaohui
    Wan, Xiaomin
    Peng, Liubao
    Peng, Ye
    Ma, Fang
    Liu, Qiao
    Tan, Chongqing
    [J]. BMJ OPEN, 2019, 9 (12): : e031019
  • [8] Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada
    Ondhia, U.
    Conter, H.
    Owen, S.
    Zhou, A.
    Nam, J.
    Singh, S.
    Abdulla, A.
    Chu, P.
    Felizzi, F.
    Sangha, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S928 - S928
  • [9] Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
    Herbert H. Loong
    Carlos K. H. Wong
    Linda K. S. Leung
    Catherine P. K. Chan
    Andrea Chang
    Zheng-Yi Zhou
    Jipan Xie
    Meaghan Gibbs
    [J]. Cost Effectiveness and Resource Allocation, 18
  • [10] Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
    Loong, Herbert H.
    Wong, Carlos K. H.
    Leung, Linda K. S.
    Chan, Catherine P. K.
    Chang, Andrea
    Zhou, Zheng-Yi
    Xie, Jipan
    Gibbs, Meaghan
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
12345